Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBIT (2023 - 2025)

Historic EBIT for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to -$24.3 million.

  • Day One Biopharmaceuticals' EBIT fell 18182.95% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.6 million, marking a year-over-year increase of 2167.41%. This contributed to the annual value of -$217.3 million for FY2024, which is 543.81% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported EBIT of -$24.3 million as of Q3 2025, which was down 18182.95% from -$35.0 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year EBIT high stood at $29.6 million for Q3 2024, and its period low was -$114.8 million during Q2 2024.
  • Moreover, its 3-year median value for EBIT was -$50.3 million (2023), whereas its average is -$47.8 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 15761.5% in 2024, then tumbled by 18182.95% in 2025.
  • Quarter analysis of 3 years shows Day One Biopharmaceuticals' EBIT stood at -$59.5 million in 2023, then decreased by 9.77% to -$65.3 million in 2024, then surged by 62.88% to -$24.3 million in 2025.
  • Its EBIT stands at -$24.3 million for Q3 2025, versus -$35.0 million for Q2 2025 and -$41.1 million for Q1 2025.